196 related articles for article (PubMed ID: 33415954)
1. A comparison of diagnostic indicators of cervical cancer screening among women accessing through volunteer organisations and those via the organised programme in Turin (Piedmont Region, Northern Italy).
Ferrante G; Castagno R; Rizzolo R; Armaroli P; Caprioglio A; Larato C; Giordano L
Epidemiol Prev; 2020; 44(5-6 Suppl 1):115-123. PubMed ID: 33415954
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
7. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
8. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
10. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
[TBL] [Abstract][Full Text] [Related]
11. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
12. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
13. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
[TBL] [Abstract][Full Text] [Related]
14. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
15. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
16. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
[TBL] [Abstract][Full Text] [Related]
17. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
18. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
19. HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecamonica screening programme, Northern Italy.
Pasquale L; Rossi PG; Carozzi F; Domenighini S; Ruggeri C; Cecconami L; Morana C; Chiaramonte M; Chiudinelli D; Piccolomini M; Marchione R; Confortini M
J Med Screen; 2020 Dec; 27(4):207-214. PubMed ID: 32102618
[TBL] [Abstract][Full Text] [Related]
20. Five-year risk of CIN3 after short-term HPV-DNA negativity in cytology-negative women: a population-based cohort study.
Del Mistro A; Giorgi Rossi P; Frayle H; Pasquale L; Campari C; Ronco G; Zorzi M
BJOG; 2019 Oct; 126(11):1365-1371. PubMed ID: 31356722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
